非高危HCC患者局灶性肝病变的超声造影诊断策略
该回顾性双读者研究纳入348例非高危HCC患者的348个局灶性肝病变,先按临床特征进行风险分层,再对中危组构建超声造影(CEUS)诊断标准。结果显示临床风险分层鉴别恶性的敏感度和特异度分别为97.8%和69.8%,CEUS鉴别良性病变的准确度、敏感度和特异度分别为94.5%、83.0%和99.6%。
要点
- 先临床风险分层再评估CEUS特征,可提高非高危HCC患者肝病变诊断准确性。
- 中危组良性病变CEUS特征:动脉期高/等增强无廓清、各期无增强等5项。
- 动脉期高增强后轻度晚期廓清(>60秒)鉴别HCC特异度高但阳性预测值仅82.0%。
核心结论
- 先进行临床风险分层、再评估特定CEUS特征,是准确诊断非高危HCC患者局灶性肝病变的有前景策略。
研究设计与样本
- 回顾性双读者研究,纳入2012年1月至2015年12月连续的非高危HCC且接受CEUS检查的患者,共348个病变(348例患者)。
- 按基于临床特征的标准将患者分为中危组和低危组,中危组327例,低危组21例。
- 中危组基于所选CEUS特征构建鉴别良性病变和HCC的CEUS标准,并评估临床风险分层标准和CEUS标准的诊断效能。
关键影像表现/征象
- 中危组良性病变CEUS特征包括:动脉期高/等增强无廓清、各期无增强、动脉期周边不连续结节状增强、离心性增强或周边增强后中心无增强、增强分隔。
- 动脉期高增强后轻度晚期廓清(>60秒)在HCC患者中比非HCC患者更常见(P < .001)。
诊断标准与关键数值
- 临床风险分层标准鉴别恶性的敏感度和特异度分别为97.8%和69.8%。
- 中危组CEUS标准鉴别良性病变的准确度、敏感度和特异度分别为94.5%、83.0%和99.6%。
- 以动脉期高增强后轻度晚期廓清(>60秒)鉴别HCC的敏感度和特异度分别为52.6%和95.3%,阳性预测值仅82.0%。
- 中危组定义:男性、年龄>40岁、HBcAb阳性或肿瘤标志物阳性;否则为低危组。
临床应用与阅片要点
- 对非高危HCC患者,可先按临床特征分层,中危组再结合CEUS特征鉴别良恶性。
- 注意动脉期高增强后轻度晚期廓清(>60秒)虽特异度高,但阳性预测值有限,需结合其他特征。
局限性
- 低危组因样本量小未进一步分析。
- 本研究为回顾性双读者研究,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop an effective strategy for accurate diagnosis of focal liver lesions (FLLs) in patients with non-high risk for hepatocellular carcinoma (HCC).
METHODS: From January 2012 to December 2015, consecutive patients with non-high risk for HCC who underwent contrast-enhanced ultrasound (CEUS) were included in this retrospective double-reader study. All patients were stratified into 2 different risks (intermediate, low-risk) groups according to criteria based on clinical characteristics, known as clinical risk stratification criteria. For the intermediate-risk group, the CEUS criteria for identifying benign lesions and HCCs were constructed based on selected CEUS features. The diagnostic performance of the clinical risk stratification criteria, and CEUS criteria for identifying benign lesions and HCCs was evaluated.
RESULTS: This study included 348 FLLs in 348 patients. The sensitivity and specificity of the clinical risk stratification criteria for malignancy was 97.8 and 69.8%. Patients were classified as intermediate risk if they were male, or older than 40 years of age, or HBcAb positive, or having positive tumor markers. Otherwise, patients were classified as low risk. Among the 348 patients, 327 were in the intermediate-risk group and 21 were in the low-risk group. In the intermediate-risk group, the CEUS criteria for identifying benign lesions were any of the following features: 1) hyper/isoenhancement in the arterial phase without washout, 2) nonenhancement in all phases, 3) peripheral discontinuous globular enhancement in the arterial phase, 4) centrifugal enhancement or peripheral enhancement followed by no central enhancement, or 5) enhanced septa. The accuracy, sensitivity, and specificity of the CEUS criteria for identifying benign lesions were 94.5, 83.0, and 99.6%, respectively. Arterial phase hyperenhancement followed by mild and late washout (>60 seconds) was more common in HCC patients than in non-HCC patients (P < .001). Using arterial phase hyperenhancement followed by mild and late washout as the CEUS criteria for identifying HCCs, the sensitivity and specificity were 52.6 and 95.3%, but unfortunately, the positive predictive value was only 82.0%. For the low-risk group, no further analysis was performed due to the small sample size.
CONCLUSIONS: Initial clinical risk stratification followed by assessment of certain CEUS features appears to be a promising strategy for the accurate diagnosis of FLLs in patients not at high risk for HCC.
引用
- Xian, Li, Lan, et al. Strategy for Accurate Diagnosis by Contrast-Enhanced Ultrasound of Focal Liver Lesions in Patients Not at High Risk for Hepatocellular Carcinoma: A Preliminary Study. J Ultrasound Med. 2022. PMID: 36534591. doi:10.1002/jum.16151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。